Abstract

The present invention relates to a composition for enhancing immunity, comprising a Hafnia alvei-derived lipopolysaccharide and a carbomer. The composition for enhancing immunity, according to the present invention, has an excellent antigen-specific antibody formation promoting ability, and can effectively induce cellular and humoral immunity in an individual. Therefore, the composition for enhancing immunity of the present invention can be usefully utilized in various fields such as prevention of various infectious diseases caused by pathogens, immunity enhancement, vaccine assistance, and the like.

IPC Classes  ?

• A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 37/04 - Immunostimulants

Abstract

The present invention relates to an attenuated strain of chicken infectious anemia virus (CIAV), a vaccine composition for preventing chicken infectious anemia by using same, and a vaccination method. According to the present invention, the attenuated strain of CIAV obtained through 100 consecutive subcultures of a parent virus has significantly lower pathogenicity than the parent virus and a virus obtained by 45 consecutive subcultures of the parent virus, and exhibits a higher antibody titer and a longer maintenance period than commercial vaccines, and thus can be effectively utilized as a vaccine composition for preventing CIAV.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a duck-derived RNA polymerase I promoter and a recombinant vector carrying same. Using the duck-derived RNA polymerase I promoter of the present invention, avian influenza viruses can be produced with high efficiency. Furthermore, in the event of an outbreak of variant or novel avian influenza viruses, the established virus production system allows for the early acquisition of vaccine candidate libraries and diagnostic reagents, and thus is expected to minimize damage to domestic industries.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present application discloses a combination of primer sets capable of simultaneously detecting both pathogenic and non-pathogenic Newcastle Disease Virus (NDV), including mesogenic and velogenic strains. The primer sets and combinations according to the present application not only enable the rapid detection of NDV contamination with high specificity and sensitivity in various samples, including pathological examination samples in the veterinary field, but also are useful for distinguishing between NDV and pathogenic (mesogenic and velogenic) NDV and for titration, thus finding wide applications in disease monitoring in poultry farms.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6851 - Quantitative amplification

Abstract

The present invention relates to a method for diagnosing foot-and-mouth disease (FMD) using a polymerase chain reaction (PCR) technique. This method is to provide a method for high-accuracy and multiplex diagnosis of the foot-and-mouth disease virus by utilizing a semiconductor biosensor PCR technique in foot-mouth disease diagnosis. According to the present invention, the method can satisfy both the simplicity and accuracy of early diagnosis of foot-and-mouth disease, thus playing a crucial role in preventing and controlling the spread of the virus through the diagnosis and management of foot-and-mouth disease virus and the prevention of infection spread of foot-and-mouth disease virus. Additionally, the present invention has high potential value in meeting the demands for on-site early diagnosis and diagnostic kits for foot-and-mouth disease.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6825 - Nucleic acid detection involving sensors
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Provided are a chimeric virus expressing a porcine reproductive and respiratory syndrome virus (PRRSV)-derived peptide and a use thereof as a vaccine. The chimeric virus has an excellent immune stimulating effect and is useful as a vaccine that can effectively protect against PRRSV by suppressing viral amplification in target cells.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/12 - Viral antigens
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention can provide: a vaccine composition, which induces humoral immunity through the induction of a robust cellular immune response at an early stage of vaccination and, simultaneously, overcomes maternally-derived antibody (MDA) interference through the stimulation of B cell receptors if MDAs are present and enables active immunity; and a method for preventing or treating foot-and-mouth disease by using the composition.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/135 - Foot-and-mouth disease virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a recombinant foot-and-mouth disease virus, and a foot-and-mouth disease vaccine composition comprising an antigen isolated and purified from the virus, and may provide: a vaccine composition that induces a humoral immune response through a strong cellular immune response in the early stage of vaccination, and enables active immunity and allows interference from maternally-derived antibodies (MDA) to be overcome by stimulation of B cell receptors when the maternally-derived antibodies (MDA) are present; and a method for preventing or treating foot-and-mouth disease using the composition.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/135 - Foot-and-mouth disease virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present inventors found that pigs exhibit more innate immune responses and a more intensive T cell exhaustion pathway and thus are less likely to form adaptive and humoral immune responses than cattle. We suggested an innovative strategy for improving abnormal immune responses in pigs by simultaneously inducing potent cellular and humoral immune responses and employing a T cell effector as a novel vaccine adjuvant. This result can provide an important clue for understanding a difference in immune response between cattle and pigs and suggests a method for maximizing the immune response and vaccine efficacy lower in pigs than cattle.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/135 - Foot-and-mouth disease virus
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a live attenuated vaccine strain for porcine epidemic diarrhea virus, a composition comprising same, and a method for preparing same. More specifically, the present invention relates to: a live attenuated vaccine strain for porcine epidemic diarrhea virus, which is a monoclonal virus strain established by co-inoculating host cells with a plurality of gene-deficient virus strains derived from wild-type porcine epidemic diarrhea virus; a vaccine composition containing same; a method for producing same; and uses of same.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a mutant strain of European porcine reproductive and respiratory syndrome virus, in which silencing mutation is introduced into a specific site of the genome through codon pair deoptimization, and to a use thereof. The virus mutant strain provided by the present invention is attenuated and decreases in proliferative ability in pigs, compared to the wild-type strain and, as such, can be utilized as a vaccine for prevention of European porcine reproductive and respiratory syndrome.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides a recombinant expression vector comprising a gene encoding canine parvovirus 2a VP2 or 2b VP2 protein, a recombinant plant into which the vector is transformed, a vaccine composition against canine parvovirus, comprising canine parvovirus 2a VP2 or 2b VP2 protein obtained from the recombinant plant, and a composition for diagnosing canine parvovirus. When the recombinant plant of the present invention is used, canine parvovirus 2a VP2 or 2b VP2 antigen protein can be rapidly produced with high efficiency. Since the composition for diagnosing canine parvovirus according to the present invention uses a recombinant antigen protein, there is no possibility of contamination due to live virus handling, and thus the composition is safe, and the presence or absence of canine parvovirus infection can be rapidly diagnosed from a large amount of samples.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
• A61P 31/20 - Antivirals for DNA viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to an adjuvant composition for a foot-and-mouth disease vaccine. The present invention can provide induction of a strong anamnestic response through simultaneous induction of cellular and humoral immune responses in cloven-hoofed animals, such as cattle, pigs, etc., for prevention and treatment of a foot-and-mouth disease outbreak, a safe and optimized adjuvant composition, and a vaccine composition comprising same. In addition, when the foot-and-mouth disease breaks out, the present invention can be used to effectively cope with the outbreak as an emergency vaccine in the field, and can provide a stabilized systematic vaccine to cloven-hoofed animals.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/135 - Foot-and-mouth disease virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a chimeric virus of porcine reproductive and respiratory syndrome (PRRS) virus, the chimeric virus being usable as a vaccine. A PRRSV chimeric virus of the present invention is more attenuated than the parent strain thereof, and thus promotes the secretion of neutralizing antibodies while having low pathogenicity and high stability, thereby being usable as a vaccine in the effective prevention and treatment of PRRS diseases.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides: a recombinant expression vector comprising a gene encoding a porcine parvovirus VP2 protein; a recombinant plant or a recombinant insect cell transformed with the vector; and a vaccine composition for a porcine parvovirus and a composition for diagnosing porcine parvovirus, both of which contain a porcine parvovirus VP2 protein obtained from the recombinant plant or the recombinant insect cell. When the recombinant plant or the recombinant insect cell of the present invention is used, a porcine parvovirus antigenic protein can be produced with high efficiency, and a method for producing a porcine parvovirus antigenic protein by using the recombinant plant or the recombinant insect cell exhibits safety and stability superior to those of other antigen production methods. In addition, the composition for diagnosing porcine parvovirus, of the present invention, uses a recombinant antigenic protein so as to remove the possibility of contamination according to the handling of live viruses, and thus is safe, and enables rapid diagnosis of porcine parvovirus infection from a large amount of samples.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to: a rabies virus glycoprotein comprising an amino acid sequence represented by SEQ ID NO: 2; a recombinant vector for producing the glycoprotein; a transformant comprising the vector; and a vaccine composition comprising the rabies virus glycoprotein; and the like.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• A61K 39/205 - Rhabdoviridae, e.g. rabies virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a swine fever antigen fused with a porcine Fc fragment, and to a vaccine composition having an autoimmunity enhancement effect by binding an Fc fragment to a swine fever antigen, and a preparation method therefor.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/187 - Hog cholera virus
• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• C12N 15/67 - General methods for enhancing the expression
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Staphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureus vaccine and prevention related fields in future.

IPC Classes  ?

• C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• A61K 39/085 - Staphylococcus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a primer set for diagnosis of seven serotypes of foot-and-mouth disease viruses and a use thereof. Being capable of detecting seven serotypes of foot-and-mouth disease even in a low concentration of a sample, a primer set for detection of foot-and-mouth disease viruses of the present invention has high sensitivity and excellent specificity. In addition, an RT-LAMP method using the primer set for detection of foot-and-mouth disease viruses of the present invention allows gene amplification in an isothermal condition unlike conventional diagnostic methods and thus can reduce inspection time and enables a reaction even in an inexpensive apparatus. Therefore, the primer set allows the rapid and effective diagnosis of foot-and-mouth disease even in diagnosis rooms or fields that are not equipped with expensive apparatuses, reagents, and special staff and can be thus easily utilized in domestic or foreign virus diagnosis markets.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to a recombinant vector for producing a plant-derived classical swine fever antigen pmE2 protein, a transgenic plant transformed with the recombinant vector, a plant-derived classical swine fever antigen pmE2 protein expressed in the plant, and use thereof. According to the present invention, use may be made of a polynucleotide encoding the GP55 protein of classical swine fever virus; a recombinant vector carrying a polynucleotide coding for a cellulose-binding domain protein; and a transgenic plant transformed with the recombinant vector to produce a plant-derived classical swine fever antigen pmE2 protein at high efficiency, having an advantage in terms of safety and stability over other production methods. In addition, the plant-derived classical swine fever antigen protein pmE2 comprises a cellulose-binding domain (CBD) protein and thus can be usefully utilized as an effective marker for demarcating routes through which classical swine fever virus is exposed and an antibody is produced.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/12 - Viral antigens
• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to: a rabies virus glycoprotein comprising an amino acid sequence represented by SEQ ID NO: 2; a recombinant vector for producing the glycoprotein; a transformant comprising the vector; and a vaccine composition comprising the rabies virus glycoprotein; and the like.

IPC Classes  ?

• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/205 - Rhabdoviridae, e.g. rabies virus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses